Keyphrases
Tuberous Sclerosis Complex
100%
Seizure
83%
Epilepsy
82%
Mouse Model
52%
Epileptogenesis
51%
Mammalian Target of Rapamycin (mTOR)
41%
Astrocytes
28%
TSC1
26%
Rapamycin
24%
Mammalian Target of Rapamycin Pathway
22%
MTOR Inhibitor
22%
Tuberous Sclerosis
20%
Antiepileptogenic
20%
Dendritic Spines
14%
Epilepsy Treatment
12%
Knock-in Mouse Model
12%
Brain Injury
12%
Malformations of Cortical Development
11%
Kainate
10%
Acquired Epilepsy
10%
Genetic Epilepsy
9%
Pathophysiology
9%
Cerebrospinal Fluid
9%
Focal Cortical Dysplasia
9%
Post-traumatic Epilepsy
9%
Neuronal Death
8%
Cortical Malformation
8%
Electroencephalography
8%
Dendritic Injury
8%
Hippocampus
8%
Dentate Gyrus
8%
Cellular Mechanisms
7%
Glia
7%
Mammalian Target of Rapamycin Inhibition
7%
Spontaneous Seizures
7%
Cortex
6%
Pathway Activation
6%
Neuronal Ceroid Lipofuscinosis
6%
Pentylenetetrazole-induced Seizures
6%
Leptin
6%
Estrogen
6%
Infantile Spasms
6%
Epilepsy Syndrome
6%
Epilepsy Model
6%
Signaling Pathway
6%
Microglia
6%
Rodents
6%
Vigabatrin
6%
Novel Therapeutics
5%
Epileptiform Activity
5%
Neuroscience
Tuberous Sclerosis
81%
Mammalian Target of Rapamycin
46%
Epileptogenesis
45%
Astrocyte
30%
Sirolimus
24%
In Vivo
17%
Dendritic Spine
15%
Hippocampus
12%
Actin
11%
Glutamic Acid
10%
TSC1
9%
Neurotransmitter
9%
Neuronal Cell Death
9%
In Vitro
9%
Cell Signaling
9%
Post-Traumatic Epilepsy
9%
Dentate Gyrus
9%
Vertebral Column
8%
4-Aminopyridine
8%
Excitability
7%
Status Epilepticus
7%
Microglia
7%
Dysplasia
7%
Traumatic Brain Injury
7%
Neurotrauma
7%
Receptor
7%
Glia
6%
Vigabatrin
6%
Leptin
6%
Synaptic Transmission
6%
Dendrite
6%
Ion Channel
5%
Intractable Epilepsy
5%
Hypothalamus
5%
Protein Biosynthesis
5%
Pentylenetetrazol
5%
Gene Inactivation
5%
Cognitive Disorders
5%